S&P 500   4,605.61 (+0.85%)
DOW   34,660.19 (+0.51%)
QQQ   396.12 (+0.58%)
AAPL   169.28 (+2.41%)
MSFT   335.92 (+1.61%)
FB   318.31 (-1.90%)
GOOGL   2,877.14 (+1.38%)
AMZN   3,507.88 (+0.02%)
TSLA   1,142.91 (-0.16%)
NVDA   324.25 (-0.77%)
BABA   125.34 (-1.72%)
NIO   39.64 (+1.30%)
CGC   10.37 (-3.17%)
AMD   154.77 (-2.27%)
GE   95.46 (+0.49%)
MU   87.59 (+4.27%)
T   22.57 (-1.14%)
F   20.05 (+4.48%)
DIS   144.97 (+0.05%)
PFE   54.55 (+1.53%)
ACB   6.25 (-2.65%)
AMC   32.70 (-3.65%)
BA   194.13 (-1.88%)
S&P 500   4,605.61 (+0.85%)
DOW   34,660.19 (+0.51%)
QQQ   396.12 (+0.58%)
AAPL   169.28 (+2.41%)
MSFT   335.92 (+1.61%)
FB   318.31 (-1.90%)
GOOGL   2,877.14 (+1.38%)
AMZN   3,507.88 (+0.02%)
TSLA   1,142.91 (-0.16%)
NVDA   324.25 (-0.77%)
BABA   125.34 (-1.72%)
NIO   39.64 (+1.30%)
CGC   10.37 (-3.17%)
AMD   154.77 (-2.27%)
GE   95.46 (+0.49%)
MU   87.59 (+4.27%)
T   22.57 (-1.14%)
F   20.05 (+4.48%)
DIS   144.97 (+0.05%)
PFE   54.55 (+1.53%)
ACB   6.25 (-2.65%)
AMC   32.70 (-3.65%)
BA   194.13 (-1.88%)
S&P 500   4,605.61 (+0.85%)
DOW   34,660.19 (+0.51%)
QQQ   396.12 (+0.58%)
AAPL   169.28 (+2.41%)
MSFT   335.92 (+1.61%)
FB   318.31 (-1.90%)
GOOGL   2,877.14 (+1.38%)
AMZN   3,507.88 (+0.02%)
TSLA   1,142.91 (-0.16%)
NVDA   324.25 (-0.77%)
BABA   125.34 (-1.72%)
NIO   39.64 (+1.30%)
CGC   10.37 (-3.17%)
AMD   154.77 (-2.27%)
GE   95.46 (+0.49%)
MU   87.59 (+4.27%)
T   22.57 (-1.14%)
F   20.05 (+4.48%)
DIS   144.97 (+0.05%)
PFE   54.55 (+1.53%)
ACB   6.25 (-2.65%)
AMC   32.70 (-3.65%)
BA   194.13 (-1.88%)
S&P 500   4,605.61 (+0.85%)
DOW   34,660.19 (+0.51%)
QQQ   396.12 (+0.58%)
AAPL   169.28 (+2.41%)
MSFT   335.92 (+1.61%)
FB   318.31 (-1.90%)
GOOGL   2,877.14 (+1.38%)
AMZN   3,507.88 (+0.02%)
TSLA   1,142.91 (-0.16%)
NVDA   324.25 (-0.77%)
BABA   125.34 (-1.72%)
NIO   39.64 (+1.30%)
CGC   10.37 (-3.17%)
AMD   154.77 (-2.27%)
GE   95.46 (+0.49%)
MU   87.59 (+4.27%)
T   22.57 (-1.14%)
F   20.05 (+4.48%)
DIS   144.97 (+0.05%)
PFE   54.55 (+1.53%)
ACB   6.25 (-2.65%)
AMC   32.70 (-3.65%)
BA   194.13 (-1.88%)
NASDAQ:PLSE

Pulse Biosciences Stock Forecast, Price & News

$19.99
-0.31 (-1.53%)
(As of 12/1/2021 01:33 PM ET)
Add
Compare
Today's Range
$19.98
$20.79
50-Day Range
$19.99
$24.40
52-Week Range
$14.59
$45.82
Volume
652 shs
Average Volume
96,482 shs
Market Capitalization
$592.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.64
30 days | 90 days | 365 days | Advanced Chart
Receive PLSE News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulse Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Pulse Biosciences logo

About Pulse Biosciences

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PLSE
Fax
N/A
Employees
95
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.90 per share

Profitability

Net Income
$-49.85 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
14,596,000
Market Cap
$592.32 million
Optionable
Optionable

Company Calendar

Last Earnings
11/15/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/28/2022

MarketRank

Overall MarketRank

2.42 out of 5 stars

Medical Sector

160th out of 1,392 stocks

Surgical & Medical Instruments Industry

21st out of 127 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












Pulse Biosciences (NASDAQ:PLSE) Frequently Asked Questions

Is Pulse Biosciences a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulse Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Pulse Biosciences stock.
View analyst ratings for Pulse Biosciences
or view top-rated stocks.

How has Pulse Biosciences' stock been impacted by Coronavirus?

Pulse Biosciences' stock was trading at $6.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PLSE shares have increased by 214.3% and is now trading at $19.99.
View which stocks have been most impacted by COVID-19
.

When is Pulse Biosciences' next earnings date?

Pulse Biosciences is scheduled to release its next quarterly earnings announcement on Monday, February 28th 2022.
View our earnings forecast for Pulse Biosciences
.

How were Pulse Biosciences' earnings last quarter?

Pulse Biosciences, Inc. (NASDAQ:PLSE) posted its quarterly earnings data on Monday, November, 15th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.05. During the same quarter in the previous year, the business posted ($0.51) earnings per share.
View Pulse Biosciences' earnings history
.

What price target have analysts set for PLSE?

3 equities research analysts have issued 12 month target prices for Pulse Biosciences' shares. Their forecasts range from $28.00 to $43.00. On average, they anticipate Pulse Biosciences' stock price to reach $37.00 in the next year. This suggests a possible upside of 85.1% from the stock's current price.
View analysts' price targets for Pulse Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Pulse Biosciences' key executives?

Pulse Biosciences' management team includes the following people:
  • Darrin R. Uecker, President, Chief Executive Officer & Director
  • Edison Manuel, Vice President-Operations
  • Sandra A. Gardiner, CFO, Treasurer & Executive Vice President
  • David Danitz, Senior Vice President-Engineering
  • Richard Nuccitelli, Chief Science Officer

What is Darrin R. Uecker's approval rating as Pulse Biosciences' CEO?

2 employees have rated Pulse Biosciences CEO Darrin R. Uecker on Glassdoor.com. Darrin R. Uecker has an approval rating of 100% among Pulse Biosciences' employees. This puts Darrin R. Uecker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pulse Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), NVIDIA (NVDA), Portola Pharmaceuticals (PTLA), (CGC), Enphase Energy (ENPH) and Novavax (NVAX).

When did Pulse Biosciences IPO?

(PLSE) raised $20 million in an initial public offering on Wednesday, May 18th 2016. The company issued 5,000,000 shares at a price of $4.00 per share. MDB Capital Group and Feltl and Company served as the underwriters for the IPO.

What is Pulse Biosciences' stock symbol?

Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE."

Who are Pulse Biosciences' major shareholders?

Pulse Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (2.85%), Granahan Investment Management Inc. MA (1.24%), Geode Capital Management LLC (0.84%), M&G Investment Management Ltd. (0.22%), Griffin Asset Management Inc. (0.21%) and Bank of New York Mellon Corp (0.13%).
View institutional ownership trends for Pulse Biosciences
.

Which institutional investors are selling Pulse Biosciences stock?

PLSE stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Investments LP, BlackRock Inc., California State Teachers Retirement System, and Two Sigma Advisers LP.
View insider buying and selling activity for Pulse Biosciences
or view top insider-selling stocks.

Which institutional investors are buying Pulse Biosciences stock?

PLSE stock was purchased by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, M&G Investment Management Ltd., Citadel Advisors LLC, New York State Common Retirement Fund, Geode Capital Management LLC, SG Americas Securities LLC, Advisor Group Holdings Inc., and Metropolitan Life Insurance Co NY.
View insider buying and selling activity for Pulse Biosciences
or or view top insider-buying stocks.

How do I buy shares of Pulse Biosciences?

Shares of PLSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pulse Biosciences' stock price today?

One share of PLSE stock can currently be purchased for approximately $19.99.

How much money does Pulse Biosciences make?

Pulse Biosciences has a market capitalization of $592.32 million. The company earns $-49.85 million in net income (profit) each year or ($2.34) on an earnings per share basis.

How many employees does Pulse Biosciences have?

Pulse Biosciences employs 95 workers across the globe.

What is Pulse Biosciences' official website?

The official website for Pulse Biosciences is www.pulsebiosciences.com.

Where are Pulse Biosciences' headquarters?

Pulse Biosciences is headquartered at 3957 POINT EDEN WAY, HAYWARD CA, 94545.

How can I contact Pulse Biosciences?

Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at (510) 906-4600 or via email at [email protected].


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.